Zomedica Corp.
ZOMDF evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ZOMDF—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ZOMDF
Zomedica Corp. is a veterinary diagnostics and therapeutics company developing products for companion animals, with a focus on its TRUFORMA diagnostic platform and a pipeline of drug candidates.
Key risk: Continued operating losses
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Zomedica Corp..
Zomedica Corp. is a veterinary diagnostics and therapeutics company developing products for companion animals, with a focus on its TRUFORMA diagnostic platform and a pipeline of drug candidates.
- Zomedica is focused on the development of diagnostic and drug product candidates for the veterinary market, including TRUFORMA and ZM-020 [sec].
- The company reported cash & equivalents of $7.2M, total revenue of $9.5M, and a net loss of $3.8M as of 2026-06-30 [sec].
- Shareholders' equity stood at $115.4M as of 2026-06-30 [sec].
- The company expects to continue incurring losses and may never become profitable [sec].
- Drug product candidates are estimated to require three to five years of development at a cost of approximately $3 million to $5 million each before marketing approval [sec].
What works
- The company has a shareholders' equity of $115.4M as of 2026-06-30, providing a substantial capital base [sec].
- Zomedica has generated $9.5M in revenue as of 2026-06-30, indicating some commercial traction [sec].
What to weigh
- The company reported a net loss of $3.8M as of 2026-06-30 and expects to continue incurring losses for the foreseeable future [sec].
- Cash & equivalents of $7.2M as of 2026-06-30 may be limited relative to the expected development costs of $3M-$5M per drug candidate [sec].
- The company's near-term prospects depend heavily on the successful development and commercialization of its lead candidates, which face significant regulatory and clinical validation risks [sec].
From the filings
Quoted directly from source documents.
The company expects to continue incurring losses and may never become profitable.
“Even if we succeed in developing and broadly commercializing one or more of our product candidates, we expect to continue to incur losses for the foreseeable future, and we may never become profitable.”
SEC filings · November 13, 2018
Drug product candidates require significant development time and cost.
“anticipate that each of our drug product candidates will require from three to five years of development at a cost of approximately $3 million to $5 million per drug product candidate before we expect to be able to apply for marketing approval in the United States.”
SEC filings · November 13, 2018
Near-term prospects depend on successful development and commercialization of lead candidates.
“our near-term prospects, including our ability to generate material product revenue, or enter into potential strategic transactions, will depend heavily on the successful development and commercialization of one or more of our lead candidates”
SEC filings · November 13, 2018
Risks & what to watch (4)›
Key risks
- Continued operating losses — The company reported a net loss of $3.8M as of 2026-06-30 and expects losses to continue, with no guarantee of profitability [sec].
- Limited cash runway — Cash & equivalents of $7.2M as of 2026-06-30 may be insufficient to fund development costs of $3M-$5M per drug candidate [sec].
- Dependence on lead candidates — Near-term prospects depend heavily on successful development and commercialization of lead candidates, which face regulatory and clinical validation risks [sec].
- Regulatory approval uncertainty — The company must obtain FDA-CVM or USDA-CVB approval for its product candidates, which is uncertain and time-consuming [sec].
What to watch
- Progress of clinical validation studies for TRUFORMA and other lead candidates [sec].
- Cash burn rate and any additional financing activities given the $7.2M cash position as of 2026-06-30 [sec].
- Revenue growth trajectory and path to profitability [sec].
- Regulatory milestones with FDA-CVM or USDA-CVB for drug and diagnostic candidates [sec].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Zomedica Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Zomedica Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
26.3 months
D/E 0.10
Lead: Approved
1 candidate
No upcoming catalysts tracked
12 buys · 0 sells (180d)
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
4
Total value held
$11K
| Holder | Shares | Value |
|---|---|---|
| ancora advisors llc | 83,610 | $10K |
| corecap advisors, llc | 4,800 | $573 |
| gill capital partners, llc | 2,719 | $325 |
| harbour investments, inc. | 2,200 | $263 |
Short Interest
as of Apr 22, 2026- % of float
- 4.7%
- Days to cover
- 13.0
- Shares short
- 45,403,440
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ZOMDF short interestGovernance
Frequently asked questions
What is the AI investment thesis for Zomedica Corp.?
Zomedica Corp. is a veterinary diagnostics and therapeutics company developing products for companion animals, with a focus on its TRUFORMA diagnostic platform and a pipeline of drug candidates.
What is Zomedica Corp.'s lead drug candidate?
Zomedica Corp.'s most advanced tracked candidate is vetigel (Approved) for stop bleeding.
Who is the CEO of Zomedica Corp.?
Mr. Larry C. Heaton II is the chief executive officer of Zomedica Corp. (ZOMDF).
Where is Zomedica Corp. headquartered?
Zomedica Corp. (ZOMDF) is headquartered in Ann Arbor, MI, United States.
What therapeutic areas does Zomedica Corp. focus on?
Zomedica Corp. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.